[HTML][HTML] Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation …
P Armand, S Gannamaneni, HT Kim… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2008•ncbi.nlm.nih.gov
Purpose Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown
clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity
in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus
for GVHD prophylaxis in patients with lymphoma might lead to improved survival after
transplantation through a decreased incidence of disease progression.
clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity
in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus
for GVHD prophylaxis in patients with lymphoma might lead to improved survival after
transplantation through a decreased incidence of disease progression.
Abstract
Purpose
Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression.
ncbi.nlm.nih.gov